Peter Ordentlich
Founder at SYNDAX PHARMACEUTICALS, INC.
Net worth: 5 451 $ as of 30/04/2024
Network origin in Peter Ordentlich first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 44 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Peter Ordentlich via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| LIGAND PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
| The Salk Institute for Biological Studies | College/University | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| AVANIR PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Corthera, Inc.
 Corthera, Inc. Pharmaceuticals: MajorHealth Technology Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| TRAWS PHARMA, INC. | Biotechnology | Corporate Officer/Principal President | |
| Aventis, Inc. | Corporate Officer/Principal Corporate Officer/Principal | ||
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Pharmaceuticals: Major | Chairman Founder | |
| MERSANA THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Chief Operating Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Domain Associates LLC
 Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | Investment Managers | Consultant / Advisor Private Equity Investor Consultant / Advisor | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Corporate Officer/Principal Private Equity Investor Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Graduate Degree | |
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
MPM Asset Management LLC
 MPM Asset Management LLC Financial ConglomeratesFinance Part of MPM BioImpact, Inc, MPM Asset Management LLC is a company that provides venture capital. The company is based in Boston, MA. | Financial Conglomerates | Corporate Officer/Principal Private Equity Investor | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MUSC Foundation for Research Development | Director/Board Member Director/Board Member | ||
Nuon Therapeutics, Inc.
 Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| ALLERGAN PLC | Pharmaceuticals: Major | Public Communications Contact Corporate Officer/Principal | |
| University of California | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
RightCare Solutions, Inc.
 RightCare Solutions, Inc. Packaged SoftwareTechnology Services Right Care Solutions, Inc. develops a discharge decision support platform. It offers risk assessment by flagging patients at risk for readmissions when admitted to the hospital. The solution also provides recommendations regarding post-acute care and community-based services for patients. The company was founded by Eric M. Heil and Kathyrn H. Bowles in 2011 and is headquartered in Horsham, PA. | Packaged Software | Director/Board Member Director/Board Member | |
Domain LLC
 Domain LLC Investment ManagersFinance Domain LLC provides investment advice. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Founder Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Graduate Degree Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| TOBIRA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Chief Executive Officer | |
| ORIC PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
| HARPOON THERAPEUTICS, INC. | Biotechnology | Founder Director/Board Member | |
| ONCORUS, INC. | Biotechnology | Chairman Director/Board Member Director of Finance/CFO | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Director/Board Member | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member Director/Board Member | |
Aspen Neuroscience, Inc.
 Aspen Neuroscience, Inc. Medical/Nursing ServicesHealth Services Aspen Neuroscience, Inc. engages in the provision of neurological treatment services. It offers technologies for patient-specific induced pluripotent stem cell-based therapies. The company was founded by Jeanne Loring and is headquartered in San Diego, CA. | Medical/Nursing Services | Chief Executive Officer Director/Board Member | |
| ADYNXX, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
Frontier Medicines Corp.
 Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Transposon Therapeutics, Inc.
 Transposon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Chairman | |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Medical Specialties | Director/Board Member Director/Board Member | |
| METACRINE, INC. | Biotechnology | Founder Founder Founder |
Statistics
International
| United States | 49 |
| Ireland | 2 |
| United Kingdom | 2 |
Sectoral
| Health Technology | 31 |
| Consumer Services | 8 |
| Commercial Services | 5 |
| Finance | 5 |
| Technology Services | 2 |
Operational
| Director/Board Member | 350 |
| Corporate Officer/Principal | 134 |
| Independent Dir/Board Member | 111 |
| Chairman | 66 |
| Chief Executive Officer | 58 |
Most connected contacts
| Insiders | |
|---|---|
| Eckard Weber | 46 |
| Pierre Legault | 45 |
| Luke Evnin | 42 |
| Art Pappas | 42 |
| Kim Kamdar | 41 |
| Richard Heyman | 33 |
| Ivor Royston | 30 |
| Arlene Morris | 28 |
| Lori Kunkel | 27 |
| Dennis Podlesak | 27 |
| Briggs Morrison | 26 |
| Steven St. Peter | 26 |
| Allan Shaw | 23 |
| Pamela Klein | 19 |
| Fabrice Egros | 18 |
- Stock Market
- Insiders
- Peter Ordentlich
- Company connections
